Female Infertility Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

Female infertility is defined as the inability to achieve a clinical pregnancy after 12 months of regular unprotected intercourse (or 6 months for women over 35), and affects approximately 10–15% of couples globally. Female-factor causes account for approximately 40% of infertility, with combined male-female factors contributing a further 20–30%. The clinical evaluation of female infertility begins with a detailed menstrual, surgical, and sexual history; physical examination; and a structured diagnostic workup encompassing ovarian reserve testing (AMH, antral follicle count, Day 2–3 FSH), hormonal assessment (TSH, prolactin, androgens), uterine cavity evaluation (transvaginal ultrasound, hysterosalpingography or office hysteroscopy), and fallopian tube assessment.

The major categories of female infertility include ovulatory dysfunction (WHO Class I–III: hypogonadotropic hypogonadism, normogonadotropic anovulation including PCOS, and premature ovarian insufficiency), tubal factor (prior pelvic inflammatory disease, endometriosis, prior tubal surgery), uterine factor (congenital anomalies, fibroids, polyps, intrauterine adhesions), cervical factor (hostile cervical mucus, prior LEEP/cone biopsy), and unexplained infertility. Accurate diagnosis directs targeted treatment and avoids unnecessary escalation to complex interventions when simpler approaches are appropriate. Patients experiencing symptoms should seek timely evaluation by a board-certified specialist for accurate diagnosis, staging, and personalised treatment planning using current clinical guidelines.

Ovulatory dysfunction — particularly polycystic ovary syndrome (PCOS), which accounts for 80–90% of WHO Class II anovulation — responds well to first-line oral ovulation induction (letrozole, clomiphene citrate) and lifestyle modification (weight normalisation in overweight women). Hypothalamic amenorrhoea (WHO Class I) requires pulsatile GnRH or exogenous FSH/LH therapy; functional causes (excessive exercise, low body weight) are addressed with weight gain.

Tubal factor infertility — bilateral blockage from prior PID, chlamydia, endometriosis, or prior ectopic surgery — is best treated by bypassing the tubes entirely through IVF, as surgical tubal reconstruction has lower success rates and ectopic pregnancy risk. Endometriosis-related infertility benefits from surgical excision of endometriotic deposits for mild-moderate disease, with IVF as the primary option for severe or recurrent disease. Uterine septum and other congenital anomalies are corrected by hysteroscopic septoplasty. Submucosal fibroids distorting the uterine cavity require surgical removal (hysteroscopic myomectomy) before ART cycles. Intrauterine adhesions (Asherman syndrome) are treated by hysteroscopic adhesiolysis with post-operative oestrogen-progestogen therapy.

All women experiencing infertility for 12 months (or 6 months over 35) are candidates for evaluation and treatment. Women with known conditions predicting infertility — PCOS, endometriosis, prior tubal surgery, cancer treatment requiring fertility preservation — may initiate evaluation earlier. The treatment pathway is individualised based on the specific diagnosis, age (ovarian reserve declines substantially after 35, with marked decline after 38), male partner semen parameters, and couple preference regarding intervention intensity.

Age is the most important biological prognostic factor — ovarian reserve (AMH, AFC) and oocyte quality decline with age, and live birth rates per ART cycle fall from approximately 40% under 35 to 10–15% at 42–43 and near zero with own eggs at 45+. Donor egg IVF is offered to women with diminished ovarian reserve or premature ovarian insufficiency. BMI affects fertility outcomes — obesity impairs ovulation induction response and reduces IVF live birth rates; weight normalisation improves outcomes. Women with uterine factors incompatible with pregnancy may require surrogacy.

Lifestyle modification and ovulation optimisation: for overweight anovulatory women with PCOS, 5–10% body weight reduction restores ovulation in 55–80% of cases. Letrozole (2.5–7.5 mg, days 3–7) is now the preferred first-line ovulation induction agent for PCOS (superior to clomiphene in the PPCOS II trial); clomiphene citrate (50–150 mg) remains widely used. Metformin adjunctive therapy improves ovulation rates in PCOS with insulin resistance.

Controlled ovarian stimulation with gonadotrophins (FSH, hMG) for IUI — injections of FSH stimulate multiple follicle development, followed by hCG trigger and intrauterine insemination — offers cumulative live birth rates of 15–25% over 3–4 IUI cycles for unexplained or mild male factor infertility. IVF is the definitive treatment for tubal factor, severe male factor, failed ovulation induction/IUI, advanced maternal age, and diminished ovarian reserve — combining controlled stimulation, egg retrieval, ICSI/conventional fertilisation, and embryo transfer.

Surgical treatments: hysteroscopic septoplasty for uterine septum, myomectomy for submucosal fibroids, adhesiolysis for Asherman syndrome, laparoscopic excision for endometriosis. Ovarian drilling (laparoscopic) for clomiphene-resistant PCOS. Tubal cannulation or salpingostomy for proximal tubal blockage or hydrosalpinx (with IVF preferred over tubal surgery for distal disease). Shared decision-making between patient and specialist, guided by current evidence-based clinical guidelines and the patient's individual anatomy, comorbidities, and treatment goals, is essential for selecting the most appropriate treatment modality. Pre-treatment specialist consultation, review of relevant investigations, and multidisciplinary input for complex presentations ensure the best possible outcomes.

Treatment success rates depend heavily on diagnosis and age. Ovulation induction for PCOS with letrozole achieves cumulative live birth rates of 50–65% after 5 cycles in eligible women under 38 (PPCOS II trial data). IUI with ovarian stimulation provides approximately 8–15% live birth rate per cycle for unexplained infertility. IVF live birth rates per fresh transfer are approximately 40–45% under 35, 35–40% at 35–37, 25–35% at 38–40, and 10–15% at 41–43 (SART 2022 data).

Surgical correction of uterine anomalies significantly improves implantation rates — hysteroscopic myomectomy for submucosal fibroids improves clinical pregnancy rates by 30–50% in controlled studies. Endometriosis surgery improves spontaneous and IUI-assisted pregnancy rates for mild-moderate disease. Cumulatively, with appropriate treatment sequencing, over 70% of couples presenting with infertility achieve a live birth within 3 years.

Ovulation induction with gonadotrophins carries risk of ovarian hyperstimulation syndrome (OHSS) — characterised by enlarged ovaries, abdominal distension, and fluid shift. Mild-moderate OHSS occurs in 10–30% of stimulated cycles; severe OHSS in 1–2%, requiring hospitalisation. Twin and higher-order multiple pregnancies with gonadotrophin IUI carry risks of prematurity, low birth weight, and maternal complications — ultrasound monitoring and cycle cancellation when more than 2–3 dominant follicles develop is essential.

Surgical treatment risks include uterine perforation or cervical injury (hysteroscopy), intra-abdominal injury (laparoscopy), anaesthesia risks, and post-operative adhesion formation — particularly relevant for myomectomy and adhesiolysis. IVF-specific risks include OHSS, egg retrieval complications (bleeding, infection), and multiple pregnancy from multi-embryo transfer. Emotional burden of repeated treatment cycles is significant; psychological support should be integrated into infertility care.

Ovulation induction cycles are monitored with transvaginal ultrasound (days 10–14) to confirm follicle development and endometrial response, with dose titration preventing excessive response. LH surge detection triggers timed intercourse or IUI. Luteal phase support (progesterone supplementation) follows IUI in gonadotrophin-stimulated cycles. Pregnancy test at 14 days post-IUI; positive results require early obstetric ultrasound at 6–7 weeks.

After hysteroscopic procedures, patients resume normal activity within 24–48 hours; fertility can be attempted from the following menstrual cycle. Laparoscopic endometriosis surgery requires 3–7 days recovery before fertility treatment resumes. Post-IVF follow-up includes embryo development reporting, beta-hCG at 12–14 days post-transfer, and early pregnancy ultrasound. Long-term follow-up for PCOS patients includes cardiovascular and metabolic monitoring, as PCOS carries increased risk of type 2 diabetes and cardiovascular disease independent of fertility outcomes.

Ovulation induction with letrozole costs USD 10–50 per cycle (medication), with monitoring ultrasounds adding USD 200–800 per cycle in the US. Gonadotrophin IUI cycles cost USD 1,000–3,000 including medications and monitoring. IVF cycles in the US cost USD 12,000–20,000 per fresh cycle; FET USD 3,000–5,000. Donor egg IVF costs USD 25,000–40,000 in the US.

Medical tourism dramatically reduces costs: India offers complete IVF cycles for USD 2,000–4,500; donor egg cycles USD 5,000–9,000. Thailand: USD 5,000–10,000 IVF; donor egg USD 10,000–15,000. Spain and Czech Republic: EUR 4,000–7,000 own-egg IVF; EUR 6,000–12,000 donor egg. Leading fertility centres in Mumbai, Delhi, Bangkok, and Prague have ESHRE-compliant laboratories and offer internationally comparable outcomes at 60–80% lower cost than US or UK pricing. Patients should obtain itemised cost estimates from multiple providers and clarify insurance or national health system entitlement before committing to treatment. Accredited medical tourism destinations in India, Thailand, Turkey, and Mexico offer 50–80% cost reductions versus US pricing for elective procedures at internationally qualified specialist centres.

For unexplained infertility, expectant management (timed intercourse optimised with LH surge monitoring and fertility apps) is appropriate for couples under 35 with a 2-year infertility history and normal investigation results — cumulative spontaneous pregnancy rates of 25–30% over 24 months. Acupuncture is sought by many infertility patients; systematic reviews show no conclusive evidence of improved IVF success but improved patient psychological wellbeing.

For PCOS with anovulation, inositol supplementation (myo-inositol, D-chiro-inositol) has emerging evidence for improving menstrual regularity and metabolic parameters as a complement or alternative to clomiphene in mild cases. Traditional Chinese medicine and herbal remedies lack high-quality evidence for infertility treatment and may interact with hormonal medications — patients should disclose all complementary therapies to their fertility team. For women with poor prognosis using own eggs, donor egg IVF is the most effective alternative, achieving 55–65% live birth rates per transfer irrespective of recipient age.